Research of therapeutic basis of Astragalus P.E intervention based on the content of matrix metalloproteinase (MMP) protein in the serum of patients with Alzheimer's disease (AD)

Abstract

Matrix metalloproteinases have been proven to be the target of Alzheimer’s disease (AD) drugs. In this study, by monitoring the effects of different doses of Astragalus P.E on the serum level of matrix metalloproteinase (MMP) in patients with Alzheimer's disease. A cell model was established to explore the the protective effect and therapeutic basis of Astragalus P.E targeting matrix metalloproteinases on AD synapses. Using MTT to detect the effect of different doses of Astragalus P.E on the content of matrix metalloproteinase protein in the serum of patients with Alzheimer's disease; selecting the appropriate concentration and time as the modeling conditions of AD cells, transfecting PC12 cells by constructing the MMP promoter double luciferase reporter gene and Astragalus P.E was used as a treatment factor to observe the effect of Astragalus P.E on the transcription activity of MMP promoter. Observe the protective effect of Astragalus P.E on AD cell model and the effect on MMP expression. The AD cell model was transfected with MMP-siRNA to observe whether MMP is the key link in the effect of Astragalus P.E. 10 μM Astragalus P.E was used to induce PC12 cells for 24 h as the early AD cell model. Astragalus P.E can effectively inhibit the increase of transcription activity of MMP promoter induced by Astragalus P.E. Astragalus P.E can reduce the expression of MMP in PC12 cells induced by Astragalus P.E. At the same time, after transfection with MMP-siRNA plasmid, Astragalus P.E can significantly change the expression of MMP in PC12 cells induced by Astragalus P.E. Astragalus P.E targeting MMP has a protective effect on AD synapse damage, and it is a key link for the Astragalus P.E to exert medicinal effects.

Keywords:
Alzheimer's disease; serum matrix metalloproteinase protein; Astragalus P.E; therapeutic basis